Background/Aim: It is well-established knowledge that persons with nonaffective psychotic disorders often have problematic use of alcohol, cannabis and stimulants, but heroin use is usually not included. Our aim was to investigate the prevalence of heroin use disorders in patients with nonaffective psychosis. Methods: As the combination of heroin use and nonaffective psychosis is infrequent, epidemiological studies have to include large populations. The present study is acase count study using information from all psychiatric and social services in Oslo. Prevalence was calculated for four possible scenarios of minimum and maximum case counts and prevalences of nonaffective psychosis. Odds ratios were calculated for the resulting prevalences compared to the minimum and maximum prevalence of heroin use disorder in the general population. Results: We found between 39 and 56 subjects with nonaffective psychoses and comorbid heroin use disorder. The number of individuals with nonaffective psychosis was estimated to be between 692 and 1,730. This corresponds to a prevalence of heroin use disorder of between 2.3 and 8.1%. The odds ratio compared to the general population will range from 1.83 with a prevalence of heroin use disorder in the general population of 1.2% to 9.43 with a prevalence of 0.9%. Conclusion: Individuals with nonaffective psychosis are at increased risk of heroin use.

1.
Jaffe JH, Jaffe AB: Opioid related disorders; in Kaplan HI, Sadock BJ (eds): Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 2000, pp 1038–1062.
2.
Judd LL, Janowsky DS, Segal DS, Parker DC, Huey LY: Behavioral effects of methadone in schizophrenic patients. Am J Psychiatry 1981;138:243–245.
3.
Walby FA, Borg P, Eikeseth PH, et al: Use of methadone in the treatment of psychotic patients with heroin dependence (in Norwegian). Tidskr Nor Laegeforen 2000;120:195–198.
4.
Castaneda R, Galanter M, Franco H: Self-medication among addicts with primary psychiatric disorders. Compr Psychiatry 1998;30:80–83.
5.
Drake RE, McLahhlin P, Pepper B, Minkoff K: Dual diagnosis of major mental illness and substance disorder: an overview. New Dir Ment Health Serv 1991;50:3–12.
6.
Helseth V, Lykke Enger T, Johnsen J, Waal H: Substance use disorders among psychotic patients admitted to inpatient psychiatric care. Nord J Psychiatry 2009;63:72–77.
7.
Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D: Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002;62:743–755.
8.
Regier DA, Farmer ME, Rae DS, et al: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511–2518.
9.
Swartz MS, Wagner HR, Swanson JW, et al: Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006;194:164–172.
10.
Rounsaville BJ, Weissman MM, Kleber H, Wilber C: Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982;39:161–168.
11.
Farrell M, Boys A, Bebbington P, et al: Psychosis and drug dependence: Results from a national survey of prisoners. Br J Psychiatry 2002;181:393–398.
12.
Schneier FR, Siris SG: A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis 1987;175:641–652.
13.
Westermeyer J: Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict 2006;15:345–355.
14.
Cohen LJ, Gertmenian-King E, Kunik L, Weaver C, London ED, Galynker I: Personality measures in former heroin users receiving methadone or in protracted abstinence from opiates. Acta Psychiatr Scand 2005;112:149–158.
15.
Kringlen E, Torgersen S, Cramer V: A Norwegian psychiatric epidemiological study. Am J Psychiatry 2001;158:1091–1098.
16.
Bretteville-Jensen AL, Amundsen EJ: Heroinforbruk og heroinbeslag i Norge (Heroin consumption and heroin use in Norway); SIRUS Report. Oslo, Norwegian Institute for Alcohol and Drug Research, 2009.
17.
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8–19.
18.
Bijl RV, Ravelli A, Zessen G: Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998;33:587–595.
19.
Buchanan RW, Carpenter WT: Schizophrenia and other psychotic disorders; in Kaplan H, Sadock B (eds): Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 2005, pp 1329–1558.
20.
Frick U, Rehm J, Zullino D, Fernando M, Wiesbeck G, Ammann J, Uchtenhagen A: Long-term follow-up of orally administered diacetylmorphine substitution treatment. Eur Addict Res 2010;16:131–138.
21.
Haasen C, Verthein U, Eiroa-Orosa FJ, Schaefer I, Reimer J: Is heroin-assisted treatment effective for patients with no previous maintenance treatment? Results from a German randomised controlled trial. Eur Addict Res 2010;16:124–130.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.